SNTG2

SNTG2 (gamma-2-syntrophin) is a neuronal scaffolding protein that binds the C-terminal region of dystrophin and dystrophin-related proteins via its syntrophin unique domain, linking it to a modified dystrophin-associated protein complex expressed selectively in central neurons (PMID:10747910). Its PDZ domain directly engages the C-terminus of the voltage-gated sodium channel SCN5A, shifting channel activation kinetics and conferring mechanosensitivity in intestinal smooth muscle cells (PMID:12429735). The same PDZ domain mediates interactions with the autism-associated synaptic adhesion molecules neuroligin-3 and neuroligin-4X, and autism-linked missense mutations in these neuroligins disrupt SNTG2 binding (PMID:17292328).

1. 2000 High

   Identification of SNTG2 as a new syntrophin family member that directly binds dystrophin's C-terminus established that the dystrophin-associated protein complex in central neurons includes a neuron-specific syntrophin isoform.

   Evidence Yeast two-hybrid, GST pull-down, immunohistochemistry, and RNA in situ hybridization in rat and human tissues

   PMID:10747910

   Open questions at the time

   • No knockout or knockdown phenotype reported
   • Whether SNTG2 competes with other syntrophins for dystrophin binding sites is unresolved
   • Subcellular localization within neurons (e.g., synaptic vs. somatic) was not precisely defined
2. 2002 High

   Demonstration that SNTG2's PDZ domain binds the SCN5A C-terminus and controls channel gating and mechanosensitivity revealed a direct ion-channel-regulatory function for this scaffolding protein.

   Evidence Yeast two-hybrid and GST pull-down for binding; whole-cell patch-clamp in co-transfected HEK293 cells and peptide-disruption experiments in native intestinal smooth muscle cells

   PMID:12429735

   Open questions at the time

   • In vivo consequences of SNTG2 loss on SCN5A function have not been tested
   • Whether SNTG2 regulates other voltage-gated channels via its PDZ domain is unknown
   • Structural basis of the PDZ–SCN5A interaction has not been resolved
3. 2007 Medium

   Discovery that SNTG2 binds neuroligins 3 and 4X—and that autism-associated mutations impair this interaction—implicated SNTG2 in the postsynaptic scaffolding of autism-relevant adhesion molecules.

   Evidence Yeast two-hybrid screen and co-immunoprecipitation with wild-type and autism-mutant neuroligin constructs

   PMID:17292328

   Open questions at the time

   • No cellular or synaptic phenotype was reported upon disruption of the NL–SNTG2 interaction
   • Whether SNTG2 links neuroligins to the dystrophin complex at synapses has not been shown
   • The finding has not been independently replicated in a second laboratory

• The in vivo physiological roles of SNTG2 remain undefined: no genetic loss-of-function model or human disease association has been reported, and whether its PDZ-domain partners (SCN5A, neuroligins) are regulated simultaneously or in distinct tissue contexts is unresolved.
• No animal knockout or conditional deletion phenotype exists
• Full interactome of the SNTG2 PDZ domain has not been profiled
• Role of SNTG2 in synaptic versus extra-synaptic compartments is undefined